Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets.
about
A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motilitySGF29 and Sry pathway in hepatocarcinogenesisNovel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and developmentThe FUSE Binding Protein Is a Cellular Factor Required for Efficient Replication of Hepatitis C VirusMolecular classification and novel targets in hepatocellular carcinoma: recent advancementsCooperative antiproliferative effect of coordinated ectopic expression of DLC1 tumor suppressor protein and silencing of MYC oncogene expression in liver cancer cells: Therapeutic implicationsA meta-analysis of array-CGH studies implicates antiviral immunity pathways in the development of hepatocellular carcinoma.Molecular genetics of hepatocellular neoplasia.Collagen triple helix repeat containing 1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation and motility.Molecular pathology of hepatic neoplasms: classification and clinical significance.ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinomaPrognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers.Exploring genomic profiles of hepatocellular carcinoma.Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.Focal gains of VEGFA and molecular classification of hepatocellular carcinomaIdentification of potential driver genes in human liver carcinoma by genomewide screening.Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches.Exploration of liver cancer genomes.The male-specific factor Sry harbors an oncogenic function.Development of Cell-Permeable, Non-Helical Constrained Peptides to Target a Key Protein-Protein Interaction in Ovarian Cancer.SRY and OCT4 Are Required for the Acquisition of Cancer Stem Cell-Like Properties and Are Potential Differentiation Therapy Targets.Molecular classification of hepatocellular carcinoma: potential therapeutic implications.TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.Development of Cell-Permeable, Non-Helical Constrained Peptides to Target a Key Protein-Protein Interaction in Ovarian Cancer
P2860
Q24303454-6D01FC01-7F40-42B2-A3EB-BC9694FEBF04Q26795760-05C98258-5C47-42A5-95E1-5F458EB60AD5Q26851211-57090621-544B-46CC-908B-37B43E242B50Q27486114-65FEBAF5-FB60-4C6C-A0D0-44E51592080EQ28383646-D9DA6971-4E7E-44D5-B521-88910AE0D15CQ28384501-F1645E48-9DFF-46C0-AE82-3E6AA3BFAC1FQ31043530-EAAAE25E-5F0A-4966-81BC-0C6F28E282A5Q33680701-4E1F3A6A-0EB1-45B4-BC9C-0721DF5822E0Q33882067-F8D5148D-8C0F-412F-9A05-0DC210DDC35EQ34954493-9DCDE8F5-BAB6-4861-95F3-8365D29D1182Q35051418-474F7021-B620-4902-8A2D-B8135C2BBCECQ36233866-E0C5954C-6282-41BD-BCD4-66BF88FB515FQ36393332-644A0E1C-C6D6-4997-913C-7B5E4E789FDFQ36917485-F6B6931D-6846-4E7D-A1D0-7AF6323D64B1Q36984575-9EF29C47-29C1-41CD-ADF0-85F1B5A5C4AAQ37360110-58AA2A21-C40C-4973-8533-785142FA090FQ37857056-752A0A31-9CCB-47ED-A76B-37F0C45024CEQ38182833-047CE58E-AA8B-4568-8EA1-9FA6AE42CCC9Q39119225-633ACE0C-E962-433B-99BE-F9EB1F945376Q39130754-2AA9FF26-942D-45B3-AF73-DAD995E3E84FQ40900140-3AF67C08-C21A-4954-8CF9-0F3C6296CCA2Q43059019-CEF0344A-4538-42DC-8436-9DCDE094F127Q51579117-79B78593-7078-4865-99A1-5F2B5C03EC61Q58613115-37AC8ACE-5E6E-45A9-8A01-5591CDF8948F
P2860
Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Genetically distinct and clini ...... putative therapeutic targets.
@ast
Genetically distinct and clini ...... putative therapeutic targets.
@en
Genetically distinct and clini ...... putative therapeutic targets.
@nl
type
label
Genetically distinct and clini ...... putative therapeutic targets.
@ast
Genetically distinct and clini ...... putative therapeutic targets.
@en
Genetically distinct and clini ...... putative therapeutic targets.
@nl
prefLabel
Genetically distinct and clini ...... putative therapeutic targets.
@ast
Genetically distinct and clini ...... putative therapeutic targets.
@en
Genetically distinct and clini ...... putative therapeutic targets.
@nl
P2093
P1433
P1476
Genetically distinct and clini ...... : putative therapeutic targets
@en
P2093
Akiko Kokubu
Fumie Hosoda
Hidenori Ojima
Hiroto Katoh
Johji Inazawa
Setsuo Hirohashi
Tadashi Kondo
Tatsuhiro Shibata
Tomoo Kosuge
P304
P356
10.1053/J.GASTRO.2007.08.038
P407
P577
2007-11-01T00:00:00Z